...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The American Journal of Tropical Medicine and Hygiene >Testing of novel dengue virus 2 vaccines in African green monkeys: Safety, immunogenicity, and efficacy
【24h】

Testing of novel dengue virus 2 vaccines in African green monkeys: Safety, immunogenicity, and efficacy

机译：在非洲绿猴中测试新型登革热病毒2疫苗的安全性，免疫原性和功效

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The immunogenicity and safety of three novel host-range vaccines containing deletions in the transmembrane domain of dengue virus serotype 2 (DV2) E glycoprotein were evaluated in African green monkeys. The shorter transmembrane domains are capable of functionally spanning an insect but not a mammalian cell membrane, resulting in production of viral mutants that have reduced infectivity in mammalian hosts but efficient growth in insect cells. Groups of four monkeys received one dose each of test vaccine candidate with no booster immunization. After immunization, levels of viremia produced by each vaccine were determined by infectious center assay. Vaccine recipient immune response to wild-type DV2 challenge was measured on Day 57 by enzyme-linked immunosorbent assay and plaque reduction neutralization test. Two vaccines, DV2ΔGVII and DV2G460P, generated neutralizing antibody in the range of 700-900 50% plaque reduction neutralization test units. All three vaccine strains decreased the length of viremia by at least two days. No safety concerns were identified.
机译：在非洲绿猴中评估了三种新型登革热范围疫苗的免疫原性和安全性，这些疫苗在登革热病毒血清型2（DV2）E糖蛋白的跨膜结构域中缺失。较短的跨膜结构域能够在功能上跨越昆虫，但不能跨越哺乳动物细胞膜，从而产生病毒突变体，该突变体在哺乳动物宿主中的感染力降低，但在昆虫细胞中有效生长。四只猴子组成的组每只接受一剂未进行加强免疫的待测疫苗。免疫后，通过感染中心测定法确定每种疫苗产生的病毒血症水平。在第57天，通过酶联免疫吸附测定和噬斑减少中和试验测量了对野生型DV2攻击的疫苗接受者免疫应答。两种疫苗DV2ΔGVII和DV2G460P在700-900 50％噬菌斑减少中和试验单位范围内产生中和抗体。所有这三种疫苗株都使病毒血症的时间缩短了至少两天。没有发现安全隐患。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号